Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127573301 | 12757330 | 1 | I | 201604 | 20160912 | 20160919 | 20160919 | EXP | GB-MHRA-EYC 00144852 | GB-CONCORDIA PHARMACEUTICALS INC.-GSH201609-004559 | CONCORDIA | 85.00 | YR | M | Y | 0.00000 | 20160919 | OT | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127573301 | 12757330 | 1 | PS | DIGOXIN. | DIGOXIN | 1 | Oral | Y | U | 20405 | QD | ||||||||
| 127573301 | 12757330 | 2 | SS | BISOPROLOL | BISOPROLOL | 1 | Oral | EVERY MORNING | Y | U | 0 | 10 | MG | QD | |||||
| 127573301 | 12757330 | 3 | SS | RAMIPRIL. | RAMIPRIL | 1 | Oral | 5MG EVERY MORNING AND 2.5MG EVERY NIGHT | Y | U | 0 | 7.5 | MG | ||||||
| 127573301 | 12757330 | 4 | C | ATORVASTATIN | ATORVASTATIN | 1 | 0 | ||||||||||||
| 127573301 | 12757330 | 5 | C | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | 0 | ||||||||||||
| 127573301 | 12757330 | 6 | C | FERROUS SULFATE. | FERROUS SULFATE | 1 | 0 | ||||||||||||
| 127573301 | 12757330 | 7 | C | FINASTERIDE. | FINASTERIDE | 1 | 0 | ||||||||||||
| 127573301 | 12757330 | 8 | C | FOLIC ACID. | FOLIC ACID | 1 | 0 | ||||||||||||
| 127573301 | 12757330 | 9 | C | FUROSEMIDE. | FUROSEMIDE | 1 | 0 | ||||||||||||
| 127573301 | 12757330 | 10 | C | HUMALOG MIX75/25 | INSULIN LISPRO | 1 | 0 | ||||||||||||
| 127573301 | 12757330 | 11 | C | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | 0 | ||||||||||||
| 127573301 | 12757330 | 12 | C | LINAGLIPTIN | LINAGLIPTIN | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127573301 | 12757330 | 1 | Left ventricular dysfunction |
| 127573301 | 12757330 | 2 | Left ventricular dysfunction |
| 127573301 | 12757330 | 3 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127573301 | 12757330 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127573301 | 12757330 | Acute kidney injury | |
| 127573301 | 12757330 | Atrial fibrillation | |
| 127573301 | 12757330 | Atrioventricular block | |
| 127573301 | 12757330 | Bradycardia | |
| 127573301 | 12757330 | Hyperkalaemia | |
| 127573301 | 12757330 | Lethargy | |
| 127573301 | 12757330 | Malaise | |
| 127573301 | 12757330 | Thirst | |
| 127573301 | 12757330 | Toxicity to various agents |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127573301 | 12757330 | 1 | 20160419 | 0 | ||
| 127573301 | 12757330 | 2 | 20160419 | 0 | ||
| 127573301 | 12757330 | 3 | 20160419 | 0 |